Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ClearPoint Neuro Q3 2026 Results: Net Loss of $7.46M, Loss Widens

ClearPoint Neuro, Inc. reported total revenue of $12.1 million for the third quarter of 2026, a 36% increase compared to the same period in 2025, driven primarily by product revenue growth. Despite the revenue increase, the company reported a net loss of $7.5 million for the quarter as operating expenses rose to $13.4 million, largely due to higher sales and marketing costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue12.18.9
Gross profit7.15.6
Profit before tax-7.5-5.9
Net income-7.5-5.9
EPS (diluted, $ a share)$-0.24$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+36.3%
Gross margin58.5%
Operating margin-52.4%
Source

10-Q filed with the SEC, NASDAQ: CLPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ClearPoint Neuro, Inc.: key numbers

Share price
$8.30Close, Nov 16
Market cap
$266M
Shares outstanding
32.05MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ClearPoint Neuro, Inc.

All →
4:06 PM ET 8-K
Financial Results

ClearPoint Neuro Financial Results

ClearPoint Neuro reported Q3 2026 revenue of $12.1 million, a 36% year-over-year increase driven by strong growth in neurosurgery navigation and therapy. The company raised its full-year 2026 revenue guidance to a range of $48.0 million to $50.0 million and reported a cash balance of $46.2 million.

“The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth. The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRAflow product integration has enabled improved operating leverage.”

Joe Burnett, President and CEO at ClearPoint Neuro

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.